CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Grant or award Chief Technology Officer acquired 27,777 shares (grant or award)
- 4 Grant or award Chief Strategy & Legal Officer acquired 34,722 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 34,722 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 24,305 shares (grant or award)
- 8-K Event Executive or director change
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 8-K Event Material agreement
- 4 Shares withheld for taxes Chief Technology Officer gave up 234 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 4,902 shares (to pay taxes)
- 4 Open-market buy Director bought 102,603 shares at an average $9.25 ($949,381)
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- 8-K Event Regulation FD disclosure · Other events
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Shares withheld for taxes Chief Medical Officer gave up 7,468 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Strategy & Legal Officer gave up 4,699 shares (to pay taxes)
Page 1 of 41 · 806 filings